The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis

BACKGROUND: Calcific uraemic arteriolopathy (CUA; calciphylaxis) is a rare disease seen predominantly in patients receiving dialysis. Calciphylaxis is characterized by poorly healing or non-healing wounds, and is associated with mortality, substantial morbidity related to infection and typically sev...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinha, Smeeta, Gould, Lisa J, Nigwekar, Sagar U, Serena, Thomas E, Brandenburg, Vincent, Moe, Sharon M, Aronoff, George, Chatoth, Dinesh K, Hymes, Jeffrey L, Miller, Stephan, Padgett, Claire, Carroll, Kevin J, Perelló, Joan, Gold, Alex, Chertow, Glenn M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757410/
https://www.ncbi.nlm.nih.gov/pubmed/35035944
http://dx.doi.org/10.1093/ckj/sfab117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757410/
https://www.ncbi.nlm.nih.gov/pubmed/35035944
http://dx.doi.org/10.1093/ckj/sfab117

Ejemplares similares